GlaxoSmithKline plc Can Pull Through Without a Split; Merrill Lynch Hikes Estimates

Valeant Pharmaceuticals: Bill Ackman Not Entirely Responsible for Pershing’s Losses

Pershing Square investors can take it easy on Bill Ackman after Oversight Committee's revelation on Tuesday

How Amgen may Impact Regeneron Q4 Earnings

Regeneron is expected to report a jump in sales and profit in its fourth quarter earnings

Why Gilead Sciences, Inc. Should Ramp M&A Deals Before its Too Late

A timely deal will do for Gilead’s stock what earning beats and share buybacks cannot

AstraZeneca Plunges on Weak Guidance, Intense Crestor Competition

AstraZeneca disclosed upbeat 4Q earnings, but its guidance fell short of the estimates due to intense competition from generic drug-makers

GlaxoSmithKline plc (ADR) Tops Revenue, Misses Core Earnings

GlaxoSmithKline surpassed revenue expectations for the quarter, but missed on the core earnings; gross margin fell substantially